Total Hepatitis A Antibody Test

Hepatitis A is one of the few serious infections you can fully prevent with a vaccine. The question this test answers is simple: are you already protected, or are you still at risk? A single blood draw tells you whether your immune system has met the virus, either through a past infection or a vaccine.

Knowing your status matters before international travel, before starting work in food service or healthcare, or anytime an outbreak hits your community. If you are protected, you can skip a vaccine you do not need. If you are not, you can get one before exposure rather than after.

What This Test Actually Measures

Total anti-HAV (hepatitis A virus antibody) is a mixture of immune proteins your body makes against the hepatitis A virus. Most of what the test detects is IgG (immunoglobulin G), the long-lasting form of antibody that persists for life after infection or successful vaccination. Some assays also pick up IgM (immunoglobulin M), the short-lived antibody that appears during a recent infection.

Because the test bundles both forms together, a positive result tells you that you have immunity, but it cannot tell you whether that immunity came from a recent infection, an old infection from childhood, or a vaccine. A negative result means your body has no detectable antibodies and you are susceptible to infection if exposed.

Why Immunity Status Matters

Hepatitis A is a viral liver infection spread mostly through contaminated food, water, or close personal contact. In children, it often passes without symptoms. In adults, it can cause weeks of fatigue, nausea, jaundice, and time away from work. In rare cases, especially in older adults or people with existing liver disease, it can progress to acute liver failure.

Antibodies neutralize the virus before it can cause illness. Once you have them, you are generally protected for life. Without them, your body has no head start against the virus, and infection is more likely to be symptomatic and severe.

How Common Is Susceptibility

A large US population analysis using NHANES (National Health and Nutrition Examination Survey) data from 2007 to 2016 found that 74.1% of US-born adults aged 20 and older were susceptible to hepatitis A, meaning they lacked protective antibodies. Only about a quarter of US adults had immunity from past infection or vaccination.

The pattern varies sharply by region. In Cambodia, 91% of mothers had antibodies, but only 32% of their 5 to 7 year old children did, reflecting improved sanitation that delays first exposure to later in life. In Japan, overall prevalence was just 17%, with near-zero antibody levels in adults under 60. Rural areas in Vietnam showed 81% antibody prevalence versus 58% in urban areas. If you grew up in a country with good sanitation and were never vaccinated, the odds are you are not protected.

Travel and Outbreak Risk

Hepatitis A is endemic in many parts of Asia, Africa, Central and South America, and Eastern Europe. International travel to these regions is the single most common reason adults get hepatitis A in countries where it is otherwise uncommon. Outbreaks also occur regularly in the US among people experiencing homelessness, people who use drugs, and men who have sex with men, with food-borne outbreaks traced to contaminated produce or imported foods.

A confirmed seropositive result means you can travel or live in a high-risk area without worrying about hepatitis A. A negative result is a clear signal to get vaccinated before your next trip or potential exposure, ideally at least two weeks before you go.

Acute Infection: Why This Test Alone Cannot Diagnose It

If you are currently symptomatic with possible hepatitis (yellowing skin, dark urine, nausea, abdominal pain, elevated liver enzymes), a total antibody test is not enough to diagnose an active case. Total antibody stays positive for decades after infection or vaccination, so it cannot tell whether the virus is in your body right now.

Acute hepatitis A is diagnosed using anti-HAV IgM specifically, often combined with liver enzymes (ALT and AST) and clinical symptoms. One large US health system review of 10,735 IgM tests found that most positive IgM results came from outpatients with liver disease but no clinical signs of acute hepatitis, and only 4 patients had true acute hepatitis A. The point: if you suspect a current infection, ask for IgM and a liver panel, not just total antibody.

Reference Ranges

Total anti-HAV is reported as either positive/negative or as a numeric value in milli-international units per milliliter (mIU/mL). Cutoffs are assay-specific, not standardized across labs, so your result will be interpreted against the cutoff used by the lab that runs the test. The thresholds below come from published studies using common chemiluminescent immunoassays in adult and pediatric populations. They are illustrative orientation, not universal targets, and your lab may use a different number.

Compare results within the same lab over time for the most meaningful interpretation. The 10 to 20 mIU/mL threshold is tied to the lower limit of detection of common assays, not to a clinically validated minimum protective level, but seropositivity above this range has been associated with protection in vaccine efficacy studies.

Tracking Your Trend

For most people, hepatitis A antibody testing is a one-time question with a binary answer: protected or not. If you are seropositive, you are likely protected for life and do not need repeat testing unless you become significantly immunosuppressed. If you are seronegative, the answer is to get vaccinated, then optionally retest a month or two after the second dose to confirm seroconversion.

In specific populations, periodic retesting matters more. People living with HIV, especially those with lower CD4 counts, have lower seroconversion rates after standard two-dose vaccination and may lose antibodies over time. Vaccination guidelines for HIV-positive individuals often include a three-dose schedule and periodic antibody monitoring to identify seroreverters who need a booster. If you are on chronic immunosuppressive therapy, the same logic applies: confirm your status after vaccination, and recheck every few years.

What to Do With a Negative Result

A seronegative result means you are not protected against hepatitis A. The action is straightforward: get the hepatitis A vaccine. The standard adult schedule is two doses six months apart. After the first dose, 90% of healthy adults develop antibodies within one month, and 100% are seropositive after the second dose. Roughly 90% remain seropositive at 13 months and most retain protection for decades.

If you have already been exposed to hepatitis A (a household contact was diagnosed, you ate contaminated food), post-exposure prophylaxis with either the vaccine or immune globulin can prevent infection if given within two weeks of exposure. This is a situation to act on quickly rather than wait for retesting.

What to Do With a Positive Result

A positive total antibody result almost always means you are protected. No additional action is needed for prevention. The one nuance: if you are currently symptomatic with hepatitis-like symptoms and the test is total antibody rather than IgM-specific, the result does not rule out an active infection. In that scenario, ask your clinician to order IgM separately along with ALT, AST, total bilirubin, and tests for hepatitis B and C to identify what is actually causing your symptoms.

When Results Can Be Misleading

A few factors can complicate interpretation:

• Assay variability: different commercial platforms use different cutoffs and can disagree near the threshold, particularly for IgM. Total antibody (IgG-dominant) results are more consistent across platforms, with one study showing 97.4% agreement among four major analyzers.
• Recent immune globulin or blood products: if you have received intravenous immunoglobulin or a hepatitis A immune globulin shot in the past few months, you may test positive from those external antibodies rather than your own immune response.
• Severe immunosuppression: in people on heavy immunosuppressive therapy or with advanced HIV, antibodies from prior vaccination can wane and produce a falsely reassuring negative result, or fail to develop after vaccination in the first place.
• False positive IgM: isolated IgM positives can result from cross-reactive antibodies to other infections, rheumatoid factor, or autoimmune disease. This is a problem for acute diagnosis, not for total antibody interpretation, but it is why clinicians should always combine serology with symptoms and liver enzymes.

Who Should Test

This test adds the most value before you need it. The highest-yield situations include international travel to regions where hepatitis A is endemic, work in food service or healthcare, men who have sex with men, people with chronic liver disease (where a hepatitis A infection would be more dangerous), people who use injection or non-injection drugs, and anyone who cannot document childhood vaccination or past infection. If you are unsure whether you were vaccinated as a child, testing is faster and often cheaper than tracking down decades-old records.